Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Entrada Therapeutics Inc (NQ: TRDA ) 17.32 -0.18 (-1.03%) Streaming Delayed Price Updated: 1:15 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Entrada Therapeutics Inc < Previous 1 2 3 4 Next > TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 13, 2024 TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Entrada Therapeutics Reports Second Quarter 2024 Financial Results August 13, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics Announces $100 Million Registered Direct Offering June 24, 2024 – The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy June 24, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Recap: Entrada Therapeutics Q4 Earnings March 13, 2024 Via Benzinga Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference June 03, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 16, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Entrada Therapeutics Reports First Quarter 2024 Financial Results May 07, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's After-Market Session April 11, 2024 Via Benzinga Insiders Buying America's Car-Mart And 2 Other Stocks April 11, 2024 Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. Via Benzinga Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying March 22, 2024 Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. Via Benzinga Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 13, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics to Present at Upcoming Investor Conferences February 07, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics Promotes Nathan J. Dowden to President January 03, 2024 From Entrada Therapeutics, Inc. Via GlobeNewswire HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know November 27, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session November 23, 2023 Via Benzinga Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today? November 22, 2023 Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session November 22, 2023 Via Benzinga Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy November 22, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics Reports Third Quarter 2023 Financial Results November 07, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics to Present at Upcoming Investor Conferences October 12, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy September 21, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community September 07, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics to Present at Upcoming Investor Conferences August 29, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics Appoints Gina Chapman to its Board of Directors August 10, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics Reports Second Quarter 2023 Financial Results August 08, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy August 01, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session June 26, 2023 Via Benzinga Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference June 06, 2023 From Entrada Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.